Clinical trials: Epilepsies, Partial
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
The primary objective was to evaluate the efficacy of eslicarbazepine acetate (ESL) administered once daily at 1200 mg or 800 mg, compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a…
- Trial name
- NCT00957372
- Testing
- eslicarbazepine acetate, ESL - Open-label Extension (Part II)
- Where
- Portugal
- Volunteers
- 253 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy
A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
A two arm, randomized, double-blind study comparing zonisamide with placebo. The zonisamide arm will consist of 100 subjects and the placebo arm of 50 subjects.
- Trial name
- NCT01546688
- Testing
- Zonisamide at targeted daily doses of 100-500 mg/day
- Where
- 36 sites in Germany, Hungary and 5 more
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Epilepsy, Partial
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
- Trial name
- NCT00160654
- Testing
- Levetiracetam
- Where
- 29 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 251 people
- Sponsor
- UCB Pharma
Partial Epilepsy
Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
The purpose of this study is to investigate whether multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) 800 mg once-daily (QD) affects the pharmacokinetics and tolerability of the components of a combined…
- Trial name
- NCT00898560
- Testing
- eslicarbazepine acetate and Microginon®, Microginon®
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Partial
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.
- Trial name
- NCT00280059
- Testing
- Pregabalin, Lamotrigine
- Where
- 102 sites in Belgium, Bulgaria and 27 more
- Volunteers
- 660 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
The object of this study is to assess the efficacy and safety of zonisamide as adjunctive therapy in patients with uncontrolled partial epilepsy.
- Trial name
- NCT01140867
- Testing
- zonisamide
- Where
- 10 sites in South Korea
- Volunteers
- 121 people
- Sponsor
- Eisai Korea Inc.
Epilepsy
Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy
To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to…
- Trial name
- OPTIMAL (NCT01498822)
- Testing
- Levetiracetam, Oxcarbazepine
- Where
- 23 sites in South Korea
- Volunteers
- 353 people
- Sponsor
- Korea UCB Co., Ltd.
Seizures
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures.
- Trial name
- NCT04244175
- Testing
- CVL-865
- Where
- 76 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Epilepsy, Temporal Lobe
Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation
The overall goal of this study is to open up the promising treatment of repetitive transcranial magnetic stimulation (rTMS), which has been shown to be effective against seizures in patients with surface neocortical foci, to a…
- Trial name
- NCT02339376
- Testing
- Low-frequency repetitive transcranial magnetic stimulation, High-frequency repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Beth Israel Deaconess Medical Center
Nonconvulsive Status Epilepticus, Subclinical Seizure
EEG Cap for Identification of Non-Convulsive Status Epilepticus
Altered mental status (AMS) is one of the most common reasons for inpatient neurology consultation. Non-convulsive status epilepticus (NCSE) is frequently on the differential diagnosis of the patient with AMS.
- Conditions
- Nonconvulsive Status Epilepticus, Subclinical Seizure, Altered Mental Status, Nonepileptic Seizures
- Trial name
- NCT03138876
- Testing
- EEG Cap, Anti-seizure medication, Standard EEG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Uncontrolled Partial Epilepsy, Ictal Hypoventilation
Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy
The purpose of this study is to determine the effects of fluoxetine on breathing mechanisms during seizures. Patients with partial epilepsy commonly have changes in their breathing mechanisms during seizures.
- Trial name
- NCT00986310
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, Davis
Partial Epilepsy
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
To evaluate the effects of eslicarbazepine acetate on cognition in comparison with placebo as adjunctive therapy in children aged 6 to 16 years old with refractory partial-onset seizures.
- Trial name
- NCT01527513
- Testing
- Eslicarbazepine acetate (BIA 2-093)
- Where
- 36 sites in Italy, Netherlands and 3 more
- Volunteers
- 123 people
- Sponsor
- Bial - Portela C S.A.
Partial Epilepsies, Partial Onset Seizures
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
The purpose of the trial is to evaluate the safety of intravenous (iv) lacosamide delivered in a single dose followed by 6.5 days of oral lacosamide treatment in subjects with partial-onset seizures.
- Trial name
- NCT00655551
- Testing
- lacosamide
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
Study to evaluate the efficacy of Lacosamide (LCM) administered in addition to 1 to ≤3 other Anti-Epileptic Drugs in subjects with epilepsy ≥4 years to <17 years of age who currently have uncontrolled partial onset seizures.
- Trial name
- NCT01921205
- Testing
- Lacosamide
- Where
- 118 sites in United States, Argentina and 26 more
- Volunteers
- 404 people
- Sponsor
- UCB Pharma